- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC numbers shine in second quarter
ADAC Laboratories continues to roll smoothly. The Milpitas, CA, nuclear medicine company last week released second-quarter financial results that showed revenues climbing 20% and net income increasing 44%.For the quarter (end-March), the company posted
ADAC Laboratories continues to roll smoothly. The Milpitas, CA, nuclear medicine company last week released second-quarter financial results that showed revenues climbing 20% and net income increasing 44%.
For the quarter (end-March), the company posted sales of $70 million, compared with $58.4 million in the same period the year before. ADAC's product revenue climbed 23%, while its service revenue grew 10%, the company said.
ADAC's net income was $5.6 million, compared with $3.9 million in the second quarter of 1996. ADAC's stock climbed 6% on April 24, the day the financials were announced, to close at $17 a share, up one point. The stock rose again on April 25 and closed at $19.50.
In other ADAC news, the company announced the results of clinical trials for Vantage ExSPECT, a new-generation version of its Vantage attenuation correction technique. In a paper presented at the International Conference of Nuclear Cardiology in Florence, Italy, researchers said that Vantage ExSPECT could lead to a reduction in false positives in cardiac imaging scans.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.
